Search for: "EISAI, INC."
Results 41 - 60
of 92
Sorted by Relevance
|
Sort by Date
31 Jul 2012, 2:08 pm
Eisai Co., 620 F.3d 1341 (Fed. [read post]
16 Oct 2006, 7:58 pm
Source: Eisai press release. [read post]
10 Feb 2012, 7:32 am
Clostridium difficile is a bacterium that can cause colitis and other intestinal conditions.The FDA said patients who develop diarrhea after taking these drugs should be checked for CDAD.The drugs called proton pump inhibitors (PPIs) are widely used for treating ulcers, acid reflux and other conditions.Other PPIs sold by prescription include Takeda Pharmaceutical Co Ltd's Dexilant and Prevacid, AstraZeneca's Prilosec and Vimovo, Santarus Inc's Zegerid, and Johnson &… [read post]
12 Oct 2010, 8:56 pm
Highlights this week included: Aricept(Donepezil) –US: Declaratory judgment jurisdiction for subsequent Paragraph IV filers: Teva Pharmaceuticals USA, Inc. v. [read post]
13 May 2009, 11:44 pm
" Pfizer, Inc. v. [read post]
3 Mar 2013, 12:06 pm
Rajanbabu 1424/CHENP/2008 EISAI R&D MANAGEMENT CO, LTD Granted P. [read post]
17 Jan 2011, 9:27 am
Eisai Co., 620 F.3d 1341 (Fed. [read post]
4 Sep 2012, 7:38 am
Sandoz, Inc., 678 F.3d 1280 (Fed. [read post]
9 Mar 2020, 7:46 am
Eisai Inc. had the exclusive right to market and distribute lorcaserin in the United States since 2012 and took over complete control of the drug, including regulatory compliance and safety monitoring, in 2017. [read post]
9 Mar 2020, 7:46 am
Eisai Inc. had the exclusive right to market and distribute lorcaserin in the United States since 2012 and took over complete control of the drug, including regulatory compliance and safety monitoring, in 2017. [read post]
9 Sep 2010, 7:09 pm
"); see also Eisai Co. [read post]
24 Jul 2008, 4:46 pm
Teleflex Inc. [read post]
14 Jan 2020, 1:24 pm
Some additional contextual information is provided by this FDA document, "Safety clinical trial shows possible increased risk of cancer with weight-loss medicine Belviq, Belviq XR (lorcaserin)": When approving [Belviq], we required the drug manufacturer, Eisai Inc., to conduct a randomized, double-blind, placebo-controlled clinical trial to evaluate the risk of heart-related problems. [read post]
1 Jul 2010, 1:32 pm
Grassley letters are available in the continuation of this blog entryBelow are links to the letters sent by Grassley to: Abbott Laboratories Amgen AstraZeneca Pharmaceuticals Boehringer Bristol-Myers Squibb Company Eisai Corporation of America Eli Lilly and Company Forest Laboratories GlaxoSmithKline Hoffman-La Roche Inc. [read post]
22 Aug 2016, 6:48 pm
Eisai-- who dismissed the Relator's FCA claims due to her failure to satisfy Rule 9(b): U.S. ex rel Jallali v. [read post]
22 Aug 2016, 6:48 pm
Eisai-- who dismissed the Relator's FCA claims due to her failure to satisfy Rule 9(b): U.S. ex rel Jallali v. [read post]
22 Nov 2010, 1:24 pm
Eisai Co. [read post]
27 Aug 2011, 7:55 pm
Eisai, 533 F.3d at 1356 (citing Richardson-Vicks Inc. v. [read post]
7 Apr 2021, 1:20 pm
This Belviq recall has resulted in Belviq lawsuits being filed against the responsible pharmaceutical company, Eisai Inc. [read post]
30 Nov 2010, 9:30 am
-based Eisai Inc. [read post]
